Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Non-Current Assets (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Non-Current Assets for 11 consecutive years, with $167.1 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 23.47% to $167.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $842.1 million through Dec 2025, down 4.49% year-over-year, with the annual reading at $167.1 million for FY2025, 23.47% down from the prior year.
  • Non-Current Assets for Q4 2025 was $167.1 million at Cartesian Therapeutics, down from $225.4 million in the prior quarter.
  • The five-year high for Non-Current Assets was $226.2 million in Q3 2024, with the low at $13.6 million in Q1 2021.
  • Average Non-Current Assets over 5 years is $105.7 million, with a median of $18.2 million recorded in 2022.
  • The sharpest move saw Non-Current Assets soared 1299.2% in 2024, then fell 23.47% in 2025.
  • Over 5 years, Non-Current Assets stood at $15.4 million in 2021, then rose by 14.95% to $17.7 million in 2022, then skyrocketed by 1107.58% to $214.3 million in 2023, then increased by 1.9% to $218.4 million in 2024, then dropped by 23.47% to $167.1 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $167.1 million, $225.4 million, and $225.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.